Lilly's new antipsychotic gets CHMP nod; Teva puts $300M into Kowa JV;

Eli Lilly's schizophrenia drug Zyphadera--the long-lasting, injectable form of the antipsychotic Zyprexa--got a recommendation from Europe's Committee for Medicinal Products for Human Use; next it faces final approval from the European Commission. Eli Lilly release

Teva Pharmaceutical Industries inked its joint-venture deal with Japan's Kowa Pharma in a 50-50 deal capitalized with $300 million from the Israeli generics maker. Teva release

The FDA warned five drugmakers--Shire, Johnson & Johnson, Novartis, Mallinckrodt, and Eli Lilly--that their promotional materials for ADHD meds were incomplete, false or misleading. Report

India's Supreme Court told the government to appoint an external patent expert to help hear Novartis' appeal on the denial of a patent for its cancer drug Glivec (Gleevec). Report

Covidien plans a $200 million restructuring program for 2009, hoping to achieve $50 million to $75 million in annual cost savings. Covidien release

Noven Pharmaceuticals announced the appointment of Peter G. Amanatides as Vice President-Quality Assurance & Quality Control, effective immediately; he previously served at DSM Pharmaceuticals. Noven release

Citing "historic instability in the market," Fluidigm announced today that it has withdrawn its registration statement for its IPO.

Emerging Drug Developer: KaloBios Pharmaceuticals

And Finally... Could anti-obesity meds be powerful antivirals, too? Report